Site Logo

Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.

Palvella Therapeutics Reports Top-Line Results from Pivotal Phase…
December 23, 2020
VALO Study Misses Primary Endpoint in Phase 3 Randomized Withdrawal Portion VALO Study Achieves Primary…
Read More
Palvella Therapeutics Completes $45 Million Series C Financing
May 28, 2020
Investor Syndicate Comprised of Leading Biotech Investors Proceeds to Accelerate Pipeline of Rare Disease Therapies
Read More
Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal…
March 6, 2020
Top-Line Data Expected in Q4 2020 for Fast Track-Designated Program Wayne, PA – March 6
Read More
Palvella Therapeutics Commences Phase 3 Portion of Phase…
November 13, 2019
Fast Track-designated program aims to be first targeted therapy addressing root cause of chronically debilitating…
Read More
Palvella Therapeutics Announces $10 Million in Funding from…
December 18, 2018
Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted…
Read More
Palvella Therapeutics Announces FDA Fast Track Designation for…
November 12, 2018
Wayne, PA – November 12, 2018 – Palvella Therapeutics, Inc., a rare disease biopharmaceutical company…
Read More
Palvella Therapeutics to Present Update on PTX-022 at…
October 19, 2018
Wayne, PA – October 19, 2018 – Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused…
Read More
Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine…
September 5, 2018
– Dr. Heron Adds Deep Expertise in Orphan Drug Development and Commercialization – Wayne, PA…
Read More